อ้างอิง ของ CYP2B6

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000197408 - Ensembl, May 2017
  2. "Human PubMed Reference:".
  3. 1 2 3 4 5 "Entrez Gene: cytochrome P450".
  4. 1 2 Hoffman SM, Nelson DR, Keeney DS. (2001). "Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19". Pharmacogenetics. 11 (8): 687–98. PMID 11692077. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  5. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW (2004). "Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants". Pharmacogenetics. 14 (1): 1–18. PMID 15128046. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  6. 1 2 3 Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, Schwab M (2007). "Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance". Pharmacogenomics. 8 (7): 743–59. doi:10.2217/14622416.8.7.743. PMID 17638512. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  7. Telenti A, Zanger UM (2008). "Pharmacogenetics of anti-HIV drugs". Annu Rev Pharmacol Toxicol. 48: 227–56. doi:10.1146/annurev.pharmtox.48.113006.094753. PMID 17883329.
  8. Rakhmanina NY, van den Anker JN (2010). "Efavirenz in the therapy of HIV infection". Expert Opin Drug Metab Toxicol. 6 (1): 95–103. Unknown parameter |month= ignored (help)
  9. Ekins S, Wrighton SA (1999). "The role of CYP2B6 in human xenobiotic metabolism". Drug Metab Rev. 31 (3): 719–54. doi:10.1081/DMR-100101942. PMID 10461547. Unknown parameter |month= ignored (help)
  10. Turpeinen M, Raunio H, Pelkonen O (2006). "The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico". Curr Drug Metab. 7 (7): 705–14. doi:10.2174/138920006778520633. PMID 17073575. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  11. Hodgson E, Rose RL (2007). "The importance of cytochrome P450 2B6 in the human metabolism of environmental chemicals". Pharmacol Ther. 113 (2): 420–8. doi:10.1016/j.pharmthera.2006.10.002. PMID 17157385. Unknown parameter |month= ignored (help)
  12. 1 2 Hofmann MH, Blievernicht JK, Klein K, Saussele T, Schaeffeler E, Schwab M, Zanger UM (2008). "Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver". J Pharmacol Exp Ther. 325 (1): 284–92. doi:10.1124/jpet.107.133306. PMID 18171905. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  13. 1 2 Croom EL, Stevens JC, Hines RN, Wallace AD, Hodgson E (2009). "Human hepatic CYP2B6 developmental expression: the impact of age and genotype". Biochem Pharmacol. 78 (2): 184–90. doi:10.1016/j.bcp.2009.03.029. PMID 19464434. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  14. 1 2 Sueyoshi T, Kawamoto T, Zelko I, Honkakoski P, Negishi M (1999). "The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene". J Biol Chem. 274 (10): 6043–6. PMID 10037683. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  15. 1 2 Wang H, Faucette S, Sueyoshi T, Moore R, Ferguson S, Negishi M, LeCluyse EL (2003). "A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression". J Biol Chem. 278 (16): 146-52. doi:10.1074/jbc.M212482200. PMID 12571232. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  16. 1 2 Faucette SR, Wang H, Hamilton GA, Jolley SL, Gilbert D, Lindley C, Yan B, Negishi M, LeCluyse EL (2004). "Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers". Drug Metab Dispos. 32 (3): 348–58. doi:10.1124/dmd.32.3.348. PMID 14977870. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  17. Faucette SR, Zhang TC, Moore R, Sueyoshi T, Omiecinski CJ, LeCluyse EL, Negishi M, Wang H (2007). "Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers". J Pharmacol Exp Ther. 320 (1): 78–80. doi:10.1124/jpet.106.112136. PMC 4091905. PMID 17041008. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  18. Remmer H, Schoene B, Fleischmann RA (1973). "Induction of the unspecific microsomal hydroxylase in the human liver". Drug Metab Dispos. 1 (1): 224–30. PMID 4149387. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  19. Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, Martin H, Beaune P, de Waziers I (1999). "Human CYP2B6: expression, inducibility and catalytic activities". Pharmacogenetics. 9 (3): 295–306. PMID 10471061. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  20. Goodwin B, Moore LB, Stoltz CM, McKee DD, Kliewer SA (2001). "Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor" (PDF). Mol Pharmacol. 60 (3): 427–31. PMID 11502872. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  21. Simonsson US, Jansson B, Hai TN, Huong DX, Tybring G, Ashton M (2003). "Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9". Clin Pharmacol Ther. 74 (1): 32–43. doi:10.1016/S0009-9236(03)00092-4. PMID 12844133. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  22. Burk O, Arnold KA, Nussler AK, Schaeffeler E, Efimova E, Avery BA, Avery MA, Fromm MF, Eichelbaum M (2005). "Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor" (PDF). Mol Pharmacol. 67 (6): 1954–65. doi:10.1124/mol.104.009019. PMID 15761118. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  23. Oscarson M, Zanger UM, Rifki OF, Klein K, Eichelbaum M, Meyer UA (2006). "Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine". Clin Pharmacol Ther. 80 (5): 440–56. doi:10.1016/j.clpt.2006.08.013. PMID 17112801. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  24. Desta Z, Saussele T, Ward B, Blievernicht J, Li L, Klein K, Flockhart DA, Zanger UM (2007). "Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro". Pharmacogenomics. 8 (6): 547–58. doi:10.2217/14622416.8.6.547. PMID 17559344. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  25. Saussele T, Burk O, Blievernicht JK, Klein K, Nussler A, Nussler N, Hengstler JG, Eichelbaum M, Schwab M, Zanger UM (2007). "Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole". Clin Pharmacol Ther. 82 (3): 265–74. doi:10.1038/sj.clpt.6100138. PMID 17344806. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  26. Qin WJ, Zhang W, Liu ZQ, Chen XP, Tan ZR, Hu DL, Wang D, Fan L, Zhou HH (2012). "Rapid clinical induction of bupropion hydroxylation by metamizole in healthy Chinese men" (PDF). Br J Clin Pharmacol. 74 (6): 999–1004. doi:10.1111/j.1365-2125.2012.04304.x. PMC 3522813. PMID 22519658. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  27. Kharasch ED, Mitchell D, Coles R, Blanco R (2008). "Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir" (PDF). Antimicrob Agents Chemother. 52 (5): 1663–9. doi:10.1128/AAC.01600-07. PMC 2346649. PMID 18285471. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  28. 1 2 Das PC, Cao Y, Rose RL, Cherrington N, Hodgson E (2008). "Enzyme induction and cytotoxicity in human hepatocytes by chlorpyrifos and N,N-diethyl-m-toluamide (DEET)". Drug Metabol Drug Interact. 23 (3–4): 237–60. PMID 19326769.CS1 maint: Multiple names: authors list (link)
  29. Feidt DM, Klein K, Hofmann U, Riedmaier S, Knobeloch D, Thasler WE, Weiss TS, Schwab M, Zanger UM (2010). "Profiling induction of cytochrome p450 enzyme activity by statins using a new liquid chromatography-tandem mass spectrometry cocktail assay in human hepatocytes" (PDF). Drug Metab Dispos. 38 (9): 1589–97. doi:10.1124/dmd.110.033886. PMID 20551241. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  30. 1 2 Ngaimisi E, Mugusi S, Minzi OM, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, Burhenne J, Aklillu E (2010). "Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients". Clin Pharmacol Ther. 88 (5): 676–84. doi:10.1038/clpt.2010.172. PMID 20881953. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  31. Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H (2008). "Inhibition and induction of human cytochrome P450 enzymes: current status". Arch Toxicol. 82 (10): 667–715. doi:10.1007/s00204-008-0332-8. PMID 18618097. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  32. Mo SL, Liu YH, Duan W, Wei MQ, Kanwar JR, Zhou SF (2009). "Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6". Curr Drug Metab. 10 (7): 730–53. doi:10.2174/138920009789895534. PMID 19702527. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  33. Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML, Fackenthal JD, Rogan PK, Ring B, Wrighton SA, Schuetz EG (2003). "Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression" (PDF). J Pharmacol Exp Ther. 307 (3): 906–22. doi:10.1124/jpet.103.054866. PMID 14551287. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  34. Stewart JJ, Berkel HJ, Parish RC, Simar MR, Syed A, Bocchini JA Jr, Wilson JT, Manno JE (2001). "Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender". J Clin Pharmacol. 41 (7): 770–8. doi:10.1177/00912700122010564. PMID 11452710. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  35. Hsyu PH, Singh A, Giargiari TD, Dunn JA, Ascher JA, Johnston JA (1997). "Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers". J Clin Pharmacol. 37 (8): 737–43. doi:10.1002/j.1552-4604.1997.tb04361.x. PMID 9378846. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  36. Burger D, van der Heiden I, la Porte C, van der Ende M, Groeneveld P, Richter C, Koopmans P, Kroon F, Sprenger H, Lindemans J, Schenk P, van Schaik R (2006). "Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism" (PDF). Br J Clin Pharmacol. 61 (2): 148–54. doi:10.1111/j.1365-2125.2005.02536.x. PMC 1885008. PMID 16433869. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  37. Nyakutira C, Röshammar D, Chigutsa E, Chonzi P, Ashton M, Nhachi C, Masimirembwa C (2008). "High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe". Eur J Clin Pharmacol. 64 (4): 357–65. doi:10.1007/s00228-007-0412-3. PMID 18057928. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  38. Mukonzo JK, Röshammar D, Waako P, Andersson M, Fukasawa T, Milani L, Svensson JO, Ogwal-Okeng J, Gustafsson LL, Aklillu E (2009). "A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans" (PDF). Br J Clin Pharmacol. 68 (5): 690–9. doi:10.1111/j.1365-2125.2009.03516.x. PMC 2791975. PMID 19916993. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  39. Yang X, Zhang B, Molony C, Chudin E, Hao K, Zhu J, Gaedigk A, Suver C, Zhong H, Leeder JS, Guengerich FP, Strom SC, Schuetz E, Rushmore TH, Ulrich RG, Slatter JG, Schadt EE, Kasarskis A, Lum PY (2010). "Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver" (PDF). Genome Res. 20 (8): 1020–36. doi:10.1101/gr.103341.109. PMC 2909567. PMID 20538623. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  40. Choudhary D, Jansson I, Schenkman JB, Sarfarazi M, Stoilov I (2003). "Comparative expression profiling of 40 mouse cytochrome P450 genes in embryonic and adult tissues". Arch Biochem Biophys. 414 (1): 91–100. doi:10.1016/S0003-9861(03)00174-7. PMID 12745259. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  41. Dutheil F, Beaune P, Loriot MA (2008). "Xenobiotic metabolizing enzymes in the central nervous system: Contribution of cytochrome P450 enzymes in normal and pathological human brain". Biochimie. 90 (3): 426–36. doi:10.1016/j.biochi.2007.10.007. PMID 17997991. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  42. Thelen K, Dressman JB (2009). "Cytochrome P450-mediated metabolism in the human gut wall". J Pharm Pharmacol. 61 (5): 541–58. doi:10.1211/jpp/61.05.0002. PMID 19405992. Unknown parameter |month= ignored (help)
  43. Leclerc J, Tournel G, Courcot-Ngoubo Ngangue E, Pottier N, Lafitte JJ, Jaillard S, Mensier E, Lhermitte M, Broly F, Lo-Guidice JM (2010). "Profiling gene expression of whole cytochrome P450 superfamily in human bronchial and peripheral lung tissues: Differential expression in non-small cell lung cancers". Biochimie. 92 (3): 292–306. doi:10.1016/j.biochi.2009.12.007. PMID 20034539. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  44. Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF (2003). "Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain". Neuropharmacology. 45 (1): 122–32. doi:10.1016/S0028-3908(03)00136-9. PMID 12814665. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  45. Meyer RP, Gehlhaus M, Knoth R, Volk B (2007). "Expression and function of cytochrome p450 in brain drug metabolism". Curr Drug Metab. 8 (4): 297–306. doi:10.2174/138920007780655478. PMID 17504219. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  46. Ferguson CS, Tyndale RF (2011). "Cytochrome P450 enzymes in the brain: emerging evidence of biological significance" (PDF). Trends Pharmacol Sci. 32 (12): 708–14. doi:10.1016/j.tips.2011.08.005. PMC 3223320. PMID 21975165. Unknown parameter |month= ignored (help)
  47. Center for Drug Evaluation and Research. "Drug Interactions & Labeling - Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers". www.fda.gov (in อังกฤษ). สืบค้นเมื่อ 2016-06-01.
  48. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Flockhart DA (2007). "Drug Interactions: Cytochrome P450 Drug Interaction Table". Indiana University School of Medicine. Retrieved on December 25, 2008.
  49. 1 2 3 4 5 6 7 8 9 10 11 12 13 Swedish environmental classification of pharmaceuticals - FASS (drug catalog) - Facts for prescribers (Fakta för förskrivare). Retrieved July 2011
  50. Rao LK, Flaker AM, Friedel CC, Kharasch ED (2016). "Role of Cytochrome P4502B6 Polymorphisms in Ketamine Metabolism and Clearance". The Journal of the American Society of Anesthesiologists. 125 (12): 1103–1112. doi:10.1097/ALN.0000000000001392. PMID 27763887.CS1 maint: Uses authors parameter (link)
  51. Meyer MR, Bach M, Welter J, Bovens M, Turcant A, Maurer HH (2013). "Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn". Anal Bioanal Chem. 405 (19): 6307–21. doi:10.1007/s00216-013-7051-6. PMID 23774830.CS1 maint: Uses authors parameter (link)
  52. 1 2 3 4 5 6 Walsky RL, Astuccio AV, Obach RS (2006). "Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6". J Clin Pharmacol. 46 (12): 1426–38. doi:10.1177/0091270006293753. PMID 17101742.CS1 maint: Uses authors parameter (link)
  53. Obach RS, Cox LM, Tremaine LM (2005). "Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study". Drug Metab. Dispos. 33 (2): 262–70. doi:10.1124/dmd.104.002428. PMID 15547048.CS1 maint: Uses authors parameter (link)
  54. Guo Z, Raeissi S, White RB, Stevens JC (1997). "Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes". Drug Metab. Dispos. 25 (3): 390–3. PMID 9172960.CS1 maint: Uses authors parameter (link)
  55. Volak LP, Ghirmai S, Cashman JR, Court MH (August 2008). "Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor". Drug Metab. Dispos. 36 (8): 1594–605. doi:10.1124/dmd.108.020552. PMC 2574793. PMID 18480186.CS1 maint: Uses authors parameter (link)
  56. Appiah-Opong R, Commandeur JN, van Vugt-Lussenburg B, Vermeulen NP (2007). "Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products". Toxicology. 235 (1–2): 83–91. doi:10.1016/j.tox.2007.03.007. PMID 17433521.CS1 maint: Uses authors parameter (link)
  57. 1 2 3 4 5 Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, Greenblatt DJ (2000). "CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants". Drug Metab. Dispos. 28 (10): 1176–83. PMID 10997936.CS1 maint: Uses authors parameter (link)
  58. http://www.medscape.com/viewarticle/748581_4

แหล่งที่มา

WikiPedia: CYP2B6 http://www.cell.com/trends/pharmacological-science... http://www.eurekaselect.com/57866/article http://www.eurekaselect.com/59240/article http://www.eurekaselect.com/70560/article http://www.medscape.com/viewarticle/748581_4 http://medicine.iupui.edu/flockhart/table.htm http://www.fda.gov/Drugs/DevelopmentApprovalProces... //www.ncbi.nlm.nih.gov/pmc/articles/PMC1885008 //www.ncbi.nlm.nih.gov/pmc/articles/PMC2346649 //www.ncbi.nlm.nih.gov/pmc/articles/PMC2574793